Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:CRDL NYSEAMERICAN:IGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$7.66+2.5%$7.01$4.73▼$9.53$490.81M0.37365,186 shs410,350 shsCRDLCardiol Therapeutics$1.32+1.2%$1.28$0.88▼$1.71$147.04M0.77560,361 shs180,553 shsIGCIGC Pharma$0.28+0.4%$0.29$0.24▼$0.50$28.23M0.5844,965 shs152,422 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+1.01%-6.86%+5.96%+39.37%+25.97%CRDLCardiol Therapeutics+3.17%-4.41%-13.91%+27.45%+16.07%IGCIGC Pharma-0.35%-5.07%-11.91%+7.95%-12.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$7.66+2.5%$7.01$4.73▼$9.53$490.81M0.37365,186 shs410,350 shsCRDLCardiol Therapeutics$1.32+1.2%$1.28$0.88▼$1.71$147.04M0.77560,361 shs180,553 shsIGCIGC Pharma$0.28+0.4%$0.29$0.24▼$0.50$28.23M0.5844,965 shs152,422 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+1.01%-6.86%+5.96%+39.37%+25.97%CRDLCardiol Therapeutics+3.17%-4.41%-13.91%+27.45%+16.07%IGCIGC Pharma-0.35%-5.07%-11.91%+7.95%-12.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.40Hold$20.00161.10% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50546.39% UpsideIGCIGC Pharma 2.50Moderate Buy$5.251,761.70% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, IGC, ORPH, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026AURAAura Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.004/29/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $24.004/8/2026IGCIGC Pharma Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $5.254/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/30/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.003/27/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)2/23/2026IGCIGC Pharma Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.75 ➝ $5.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$1.67 per shareN/ACRDLCardiol TherapeuticsN/AN/AN/AN/A$0.16 per shareN/AIGCIGC Pharma$1.27M22.22N/AN/A$0.08 per share3.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$106.19M-$1.74N/AN/AN/AN/A-78.12%-64.08%5/21/2026 (Estimated)CRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%N/AIGCIGC Pharma-$7.12M-$0.07N/AN/AN/A-583.91%-80.89%-63.75%N/ALatest CRDL, IGC, ORPH, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/11/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A3/30/2026Q4 2025AURAAura Biosciences-$0.43-$0.37+$0.06-$0.37N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A7.097.09CRDLCardiol TherapeuticsN/A4.394.39IGCIGC Pharma0.021.320.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%CRDLCardiol Therapeutics12.49%IGCIGC Pharma3.87%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences6.30%CRDLCardiol Therapeutics5.25%IGCIGC Pharma23.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5064.20 million60.16 millionNot OptionableCRDLCardiol Therapeutics20111.82 million105.95 millionNot OptionableIGCIGC Pharma61100.09 million76.41 millionN/ACRDL, IGC, ORPH, and AURA HeadlinesRecent News About These CompaniesIGC Pharma, Inc.: IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% EnrollmentMay 19 at 11:41 PM | finanznachrichten.deIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% EnrollmentMay 19 at 5:30 PM | accessnewswire.comANew to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast, Stardust Power, Lost Soldier Oil and Gas ...May 16, 2026 | finanznachrichten.deIGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau ConferenceMay 15, 2026 | accessnewswire.comAMarijuana Companies Eye Investment Boom After Trump Admin Reschedules DrugMay 2, 2026 | inc.comCannabis funding opensApril 30, 2026 | msn.comIGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment PhaseApril 28, 2026 | accessnewswire.comATLRY, CGC, IGC stocks light up on Trump pot reclassification hopes this weekApril 24, 2026 | msn.comIGC Pharma, Inc.: IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward CompletionApril 22, 2026 | finanznachrichten.deIGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward CompletionApril 22, 2026 | finance.yahoo.comIGC Pharma, Inc.: IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in DementiaApril 20, 2026 | finanznachrichten.deIGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in DementiaApril 20, 2026 | accessnewswire.comAIGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data ReadoutApril 14, 2026 | accessnewswire.comAAscendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming CatalystsApril 8, 2026 | accessnewswire.comAIGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's DiseaseApril 7, 2026 | accessnewswire.comAIGC Pharma, Inc.: IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor AwarenessMarch 30, 2026 | finanznachrichten.deIGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor AwarenessMarch 30, 2026 | accessnewswire.comAIGC Pharma (IGC) price target increased by 10.34% to 4.08March 28, 2026 | msn.comIGC Pharma, New to The Street launch 12-part national media partnershipMarch 27, 2026 | finance.yahoo.comNew to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market PositioningMarch 25, 2026 | kansascity.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRDL, IGC, ORPH, and AURA Company DescriptionsAura Biosciences NASDAQ:AURA$7.66 +0.19 (+2.54%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Cardiol Therapeutics NASDAQ:CRDL$1.32 +0.02 (+1.15%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.IGC Pharma NYSEAMERICAN:IGC$0.28 +0.00 (+0.36%) As of 12:51 PM Eastern This is a fair market value price provided by Massive. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Corpay’s Quiet Strength Is Winning Wall Street Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
